PT  - JOURNAL ARTICLE
AU  - MASAMI UEDA
AU  - TOMOHIRO IGUCHI
AU  - TAKAAKI MASUDA
AU  - HISATERU KOMATSU
AU  - SHO NAMBARA
AU  - SHOTARO SAKIMURA
AU  - HIDENARI HIRATA
AU  - RYUTARO UCHI
AU  - HIDETOSHI EGUCHI
AU  - SHUHEI ITO
AU  - KEISHI SUGIMACHI
AU  - TSUNEKAZU MIZUSHIMA
AU  - YUICHIRO DOKI
AU  - MASAKI MORI
AU  - KOSHI MIMORI
TI  - Up-regulation of <em>SLC9A9</em> Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer
DP  - 2017 May 01
TA  - Anticancer Research
PG  - 2255--2263
VI  - 37
IP  - 5
4099  - http://ar.iiarjournals.org/content/37/5/2255.short
4100  - http://ar.iiarjournals.org/content/37/5/2255.full
SO  - Anticancer Res2017 May 01; 37
AB  - Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorage-independent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.